Intensity Therapeutics Inc. has entered into an agreement with Merck to evaluate the combination of Intensity’s lead product candidate INT230-6 and Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid malignancies including pancreatic, bile duct, squamous cell, and non-MSI high colon cancers.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
